U.S. Endobronchial Ultrasound Biopsy Market: Rising Demand for Minimally Invasive Lung Diagnostics Drives Growth

The U.S. Endobronchial Ultrasound Biopsy (EBUS) Market is witnessing steady expansion as healthcare providers increasingly adopt minimally invasive diagnostic technologies for lung cancer detection and respiratory disease management. EBUS biopsy procedures have become an essential component in pulmonary diagnostics due to their ability to provide real-time imaging and accurate tissue sampling with reduced patient risk compared to traditional surgical biopsies.

According to recent industry analysis, the U.S. endobronchial ultrasound biopsy market was valued at approximately USD 32.5 million in 2025 and is projected to reach nearly USD 45.7 million by 2033, growing at a CAGR of 4.4% during the forecast period.

Key Market Trends & Insights

·        By equipment, EBUS scopes/EBUS systems segment dominated the market with the largest revenue share of 71.9% in 2025

·        By procedure, standalone EBUS lymph node biopsy procedures segment dominated the market with the largest revenue share in 2025.

·        By modality, the ion-based robotic-assisted bronchoscopy segment is expected to grow at the fastest CAGR

·        By site, the academic medical centers segment is expected to grow at the fastest CAGR

Market Size & Forecast

·        2025 Market Size: USD 32.5 Million

·        2033 Projected Market Size: USD 45.7 Million

·        CAGR (2026-2033): 4.4%

Download a free sample copy of the U.S. Endobronchial Ultrasound Biopsy market report to understand detailed coverage and inclusions in the final report

Key factors contributing to the market growth include rising incidence of lung cancer and respiratory disorders, rapid technological evolution and increasing market competition in the U.S. endobronchial ultrasound biopsy (EBUS) market. In addition, expansion of lung cancer screening programs, shift toward advanced bronchoscopy modalities driving EBUS adoption, favorable reimbursement and clinical guidelines.

Key Market Drivers

Rising Incidence of Lung Cancer

One of the major factors fueling market growth is the increasing prevalence of lung cancer in the United States. Lung cancer remains among the leading causes of cancer-related mortality, creating strong demand for accurate and early-stage diagnostic technologies. EBUS procedures play a critical role in detecting and staging lung tumors with minimal invasiveness.

Expansion of Lung Cancer Screening Programs

The rapid expansion of low-dose CT (LDCT) lung cancer screening programs across the U.S. is significantly boosting the demand for EBUS biopsy procedures. Early detection initiatives are increasing the number of suspicious lung nodules requiring confirmatory biopsies and lymph node evaluation.

Technological Advancements in Bronchoscopy

Continuous innovations in robotic-assisted bronchoscopy, electromagnetic navigation bronchoscopy, and AI-assisted imaging systems are transforming pulmonary diagnostics. Advanced technologies improve lesion targeting accuracy and enhance the effectiveness of EBUS-guided tissue sampling.

The adoption of ion-based robotic-assisted bronchoscopy systems is expected to emerge as one of the fastest-growing technological segments in the market over the coming years.

Growing Preference for Minimally Invasive Procedures

Patients and healthcare providers increasingly prefer minimally invasive diagnostic approaches that reduce pain, shorten hospital stays, and minimize post-procedure complications. EBUS procedures align perfectly with this trend, contributing to higher procedural volumes nationwide.

Competitive Landscape

The U.S. EBUS biopsy market features several prominent medical technology companies focused on product innovation, strategic partnerships, and geographic expansion. Major industry participants include:

• Olympus Corporation
• FUJIFILM Holdings Corporation
• Boston Scientific Corporation
• Cook Group
• PENTAX Medical

These companies continue investing in high-resolution imaging systems, advanced biopsy needles, and robotic bronchoscopy integration to strengthen their market presence.

Emerging Market Trends

Integration of Artificial Intelligence

AI-assisted bronchoscopy and imaging platforms are increasingly being integrated into pulmonary diagnostics. These technologies help physicians identify suspicious lesions more accurately and optimize biopsy targeting during EBUS procedures.

Increased Adoption of Robotic Bronchoscopy

Robotic-assisted bronchoscopy systems are revolutionizing lung diagnostics by enabling access to small and difficult-to-reach pulmonary nodules. The combination of robotic navigation with EBUS is improving diagnostic yield and procedural safety.

Conclusion

The U.S. Endobronchial Ultrasound Biopsy Market is evolving rapidly with strong support from technological innovation, increasing lung disease prevalence, and expanding early cancer screening initiatives. The shift toward minimally invasive diagnostics and precision medicine will continue creating significant opportunities for manufacturers, healthcare providers, and investors operating in this sector.

Grand View Research offers

√    Focused market intelligence reports on specific geographies or high-growth segments.

√    Extended forecast timelines for long-term planning.

√    Competitor Benchmarking and Supply Chain Analysis

√    Inclusion of regulatory and policy assessments.

√    Inclusion of custom data models, KPIs, or applications unique to your business

√    Specific high-impact Data Decks and Tables to support effective decision making